Blog review of $ARWR HBV deal, $ALNY Lumasiran data, $ABUS HBV RNAi update, $AKCA TEGSEDI approval: https://rnaitherapeutics.blogspot.com/2018/10/review-of-recent-rnai-related.html …
MKT The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint